Annual report pursuant to Section 13 and 15(d)

Intellectual Property, net

v3.23.3
Intellectual Property, net
12 Months Ended
Aug. 31, 2023
Intellectual Property, net  
Intellectual Property

9. Intellectual Property, net

 

The following is a list of capitalized US patents held by the Company.

 

Issued Patent #

Patent Certificate Grant Date

Patent Family

US 9,474,725 B1

10/25/2016

#1 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof

 

US 9,839,612 B2

12/12/2017

US 9,972,680 B2

05/15/2018

US 9,974,739 B2

05/22/2018

US 10,084,044 B2

09/25/2018

US 10,103,225 B2

10/16/2018

US 10,381,440

08/13/2019

US 10,374,036

08/06/2019

US 10,756,180

08/25/2020

US 11,311,559

04/26/2022

#18 Compositions and Methods for Enhanced Delivery of Antiviral Agents

US 11,700,875

07/18/2023

#20 Compositions and Methods for Sublingual Delivery of Nicotine

US 11,666,544

06/06/2023

#21 Compositions and Methods for Treating Hypertension

US 11,666,543

06/06/2023

A continuity schedule for capitalized patents is presented below:

 

 

 

August 31,

 

 

August 31,

 

 

 

2023

 

 

2022

 

Balance – beginning

 

$ 488,462

 

 

$ 364,623

 

Addition

 

 

135,862

 

 

 

131,448

 

Impairment

 

 

(106,761 )

 

 

-

 

Amortization

 

 

(54,938 )

 

 

(7,609 )

Balance – ending

 

$ 462,625

 

 

$ 488,462

 

 

At August 31, 2023 the Company has capitalized a total of $462,625 of patents. Included in the capitalized costs is $457,445 of costs associated with patents and licenses that have been filed. Also included in the capitalized costs is $5,180 of costs associated with provisional patents and pending applications which have not yet been filed.

 

The Company evaluated its patent portfolio and determined that certain pending applications had been abandoned or would not be pursued. As such, during the year ended August 31, 2023, the Company recognized an impairment loss of $106,761 (2022 - $Nil) related to those abandoned applications. The Company recognized $54,938 of amortization expense related to patents and licenses in the year ended August 31, 2023 (2022 - $7,609).